Pristiq Related Published Studies
Well-designed clinical trials related to Pristiq (Desvenlafaxine)
Is desvenlafaxine effective and safe in the treatment of menopausal vasomotor
symptoms? A meta-analysis and meta-regression of randomized double-blind
controlled studies. [2014]
Post hoc analysis of the efficacy and safety of desvenlafaxine 50 mg/day in a
randomized, placebo-controlled study of perimenopausal and postmenopausal women
with major depressive disorder. [2014]
Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled
study of perimenopausal and postmenopausal women with major depressive disorder. [2013]
Cardiovascular, cerebrovascular, and hepatic safety of desvenlafaxine for 1 year
in women with vasomotor symptoms associated with menopause. [2013]
Desvenlafaxine compared with placebo for treatment of menopausal vasomotor
symptoms: a 12-week, multicenter, parallel-group, randomized, double-blind,
placebo-controlled efficacy trial. [2013]
Randomized placebo- and active-controlled study of desvenlafaxine for menopausal vasomotor symptoms. [2011.11.08]
Open-label treatment with desvenlafaxine in postmenopausal women with major depressive disorder not responding to acute treatment with desvenlafaxine or escitalopram. [2011.03.01]
Pharmacokinetics of venlafaxine extended release 75 mg and desvenlafaxine 50 mg in healthy CYP2D6 extensive and poor metabolizers: a randomized, open-label, two-period, parallel-group, crossover study. [2011]
Clinical outcomes following switch from venlafaxine ER to desvenlafaxine in
nonresponders and responders. [2011]
Short-term efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder. [2010.08]
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. [2010.07]
Desvenlafaxine for the prevention of relapse in major depressive disorder: results of a randomized trial. [2010.02]
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two randomized placebo-controlled trials for the practicing physician. [2010.01]
Short-term efficacy and safety of desvenlafaxine in a randomized,
placebo-controlled study of perimenopausal and postmenopausal women with major
depressive disorder. [2010]
Retrospective analysis of suicidality in patients treated with the antidepressant
desvenlafaxine. [2010]
Analysis by age and sex of efficacy data from placebo-controlled trials of
desvenlafaxine in outpatients with major depressive disorder. [2010]
Analysis of the effect of desvenlafaxine on anxiety symptoms associated with
major depressive disorder: pooled data from 9 short-term, double-blind,
placebo-controlled trials. [2010]
Desvenlafaxine for the prevention of relapse in major depressive disorder:
results of a randomized trial. [2010]
Clinical utility of desvenlafaxine 50 mg/d for treating MDD: a review of two
randomized placebo-controlled trials for the practicing physician. [2010]
Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies. [2009.06]
An integrated analysis of the safety and tolerability of desvenlafaxine compared with placebo in the treatment of major depressive disorder. [2009.04]
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. [2009.03]
Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: a double-blind, randomized, placebo-controlled trial of efficacy and safety. [2009.01.22]
Efficacy, safety, and tolerability of fixed-dose desvenlafaxine 50 and 100 mg/day for major depressive disorder in a placebo-controlled trial. [2008.09]
Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. [2008.01]
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in adult outpatients with major depressive disorder. [2007.11]
A randomized, double-blind, placebo-controlled trial of desvenlafaxine succinate in the treatment of major depressive disorder. [2007.11]
A double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine succinate in the treatment of major depressive disorder. [2007.05]
Well-designed clinical trials possibly related to Pristiq (Desvenlafaxine)
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. [2011.02]
Efficacy of antidepressants for dysthymia: a meta-analysis of placebo-controlled
randomized trials. [2011]
Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder. [2010.11]
Pharmacological and clinical profile of newer antidepressants: implications for
the treatment of elderly patients. [2010]
Identifying meaningful differences in vasomotor symptoms among menopausal women. [2008.07]
Effect of terbinafine and voriconazole on the pharmacokinetics of the antidepressant venlafaxine. [2008.02]
Pharmacokinetic/pharmacodynamic modelling of venlafaxine: pupillary light reflex as a test system for noradrenergic effects. [2008]
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double-blind, randomised 6-month comparative trial with citalopram. [2004.12]
A double blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. [2003.12]
Venlafaxine in neuropathic pain following treatment of breast cancer. [2002]
Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and ethanol. [1997.11]
Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam. [1995.04]
Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite. [1992.08]
Other research related to Pristiq (Desvenlafaxine)
Efficacy of desvenlafaxine succinate for menopausal hot flashes. [2014]
Efficacy and safety of desvenlafaxine treatment for hot flashes associated with
menopause: a meta-analysis of randomized controlled trials. [2013]
An evaluation of sexual functioning in employed outpatients with major depressive
disorder treated with desvenlafaxine 50 mg or placebo. [2013]
Lack of a pharmacokinetic drug-drug interaction with venlafaxine
extended-release/indinavir and desvenlafaxine extended-release/indinavir. [2012]
The effect of dose titration and dose tapering on the tolerability of
desvenlafaxine in women with vasomotor symptoms associated with menopause. [2012]
Tolerance to desvenlafaxine in rapid metabolizing depressed patients. [2011.03]
The pharmacokinetics and safety of desvenlafaxine in subjects with chronic renal impairment. [2011.01]
Desvenlafaxine in the treatment of major depressive disorder. [2011]
Desvenlafaxine for major depressive disorder: incremental clinical benefits from a second-generation serotonin-norepinephrine reuptake inhibitor. [2010.12]
Assessment of infant dose through milk in a lactating woman taking amisulpride and desvenlafaxine for treatment-resistant depression. [2010.12]
Desvenlafaxine as a possible cause of acquired hemophilia. [2010.11]
HAM-D17 and HAM-D6 sensitivity to change in relation to desvenlafaxine dose and baseline depression severity in major depressive disorder. [2010.11]
Retrospective analysis of suicidality in patients treated with the antidepressant desvenlafaxine. [2010.08]
Analysis by age and sex of efficacy data from placebo-controlled trials of desvenlafaxine in outpatients with major depressive disorder. [2010.06]
Analysis of the effect of desvenlafaxine on anxiety symptoms associated with major depressive disorder: pooled data from 9 short-term, double-blind, placebo-controlled trials. [2010.03]
Correction of venlafaxine- and duloxetine-induced transaminase elevations with desvenlafaxine in a patient with Gilbert's syndrome. [2010.01]
Desvenlafaxine succinate: a newer antidepressant for the treatment of depression and somatic symptoms. [2010.01]
Mania possibly induced by desvenlafaxine. [2010.01]
Efficacy, Safety, and Tolerability of Desvenlafaxine 50 mg/d for the Treatment of Major Depressive Disorder:A Systematic Review of Clinical Trials. [2010]
Desvenlafaxine and escitalopram for the treatment of postmenopausal women with
major depressive disorder. [2010]
Discontinuation symptoms and taper/poststudy-emergent adverse events with desvenlafaxine treatment for major depressive disorder. [2009.11]
Assessing the efficacy of desvenlafaxine for improving functioning and well-being outcome measures in patients with major depressive disorder: a pooled analysis of 9 double-blind, placebo-controlled, 8-week clinical trials. [2009.10]
[Non-hormonal treatment for vasomotor symptoms during menopause: role of desvenlafaxine] [2009.10]
Desvenlafaxine: a new serotonin-norepinephrine reuptake inhibitor for the treatment of adults with major depressive disorder. [2009.06]
Desvenlafaxine: a new antidepressant or just another one? [2009.04]
An integrated analysis of the efficacy of desvenlafaxine compared with placebo in patients with major depressive disorder. [2009.03]
Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers. [2009.02]
A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. [2009.02]
The Effects of Desvenlafaxine and Paroxetine on the Pharmacokinetics of the Cytochrome P450 2D6 Substrate Desipramine in Healthy Adults. [2009.02]
A placebo-controlled study evaluating the efficacy and safety of flexible-dose desvenlafaxine treatment in outpatients with major depressive disorder. [2009.01]
Desvenlafaxine, a serotonin-norepinephrine uptake inhibitor for major depressive disorder, neuropathic pain and the vasomotor symptoms associated with menopause. [2009.01]
Analysis of depressive symptoms in patients with major depressive disorder treated with desvenlafaxine or placebo. [2009]
An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects. [2008.12]
Desvenlafaxine succinate for major depressive disorder: a critical review of the evidence. [2008.12]
Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system. [2008.11]
Desvenlafaxine: another "me too" drug? [2008.10]
An Assessment of Drug-Drug Interactions: The Effect of Desvenlafaxine and Duloxetine on the Pharmacokinetics of the CYP2D6 Probe Desipramine in Healthy Subjects. [2008.09.22]
Desvenlafaxine succinate for the treatment of major depressive disorder. [2008.08]
A pooled analysis of two placebo-controlled trials of desvenlafaxine in major depressive disorder. [2008.07]
Efficacy, safety, and tolerability of desvenlafaxine 50 mg/day and 100 mg/day in outpatients with major depressive disorder. [2008.07]
Desvenlafaxine succinate for major depressive disorder. [2008.07]
Alleviation of thermoregulatory dysfunction with the new serotonin and norepinephrine reuptake inhibitor desvenlafaxine succinate in ovariectomized rodent models. [2007.03]
Other possibly related research studies
New products and regimens (since 2003). [2007.10]
Venlafaxine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder. [2007.08]
High performance liquid chromatography-electrospray ionization mass spectrometry (HPLC-MS/ESI) method for simultaneous determination of venlafaxine and its three metabolites in human plasma. [2007.05.01]
CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine. [2006.10]
CYP2D6 genotype and venlafaxine-XR concentrations in depressed elderly. [2006.06]
Anesthesiologist suicide with atracurium. [2006.03]
A pilot study of newer antidepressant concentrations in cord and maternal serum and possible effects in the neonate. [2004.09]
Massive venlafaxine overdose resulted in a false positive Abbott AxSYM urine immunoassay for phencyclidine. [2003]
Time course of clinical response to venlafaxine: relevance of plasma level and chirality. [2004.02]
Fatality related to a 30-g venlafaxine overdose. [2003.12]
High-performance liquid chromatographic method with diode array detection for identification and quantification of the eight new antidepressants and five of their active metabolites in plasma after overdose. [2003.10]
Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine. [2003.09]
Melperone is an inhibitor of the CYP2D6 catalyzed O-demethylation of venlafaxine. [2003.01]
Venlafaxine: the relationship between dose, plasma concentration and clinical response in depressive patients. [2002.12]
Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability. [2002.08]
Combining bupropion SR with venlafaxine, paroxetine, or fluoxetine: a preliminary report on pharmacokinetic, therapeutic, and sexual dysfunction effects. [2002.03]
Rapid high-performance liquid chromatographic measurement of venlafaxine and O-desmethylvenlafaxine in human plasma. Application to management of acute intoxications. [2001.09.05]
A mixed-drug intoxication involving venlafaxine and verapamil. [2000.07]
|